Pelvic Neurofunctional Medicine

Endometriosis care often focuses on a single question: where is the disease, and can it be removed?

ESSI’s clinical model starts one level deeper: pelvic pain and pelvic dysfunction are frequently driven by a network of interacting systems — disease and inflammation, pelvic nerves, pelvic floor muscles, bladder and bowel pathways, and the body’s pain-processing circuits.

Pelvic Neurofunctional Medicine is ESSI’s framework for treating that network. It integrates nerve-sparing excision when disease is present, diagnostic and therapeutic nerve blocks, targeted pelvic Botox, and neuromodulation (neurostimulation) for selected refractory phenotypes.

The goal is to treat pain and function together, using mechanism-based decisions rather than one-label assumptions.

Why ESSI Is Unusually Comprehensive

Pelvic Neurofunctional Medicine requires unusual breadth:

Advanced endometriosis surgery, pelvic neuroanatomy literacy, bladder and bowel function pathways, and the procedural skillset to perform blocks, Botox, and neuromodulation evaluation.

Many centers excel in a single lane. ESSI is built to integrate these lanes into one coherent model. Key differentiators include:

A surgical philosophy that explicitly emphasizes nerve-sparing technique and protection of pelvic autonomic and somatic pathways that influence bladder, bowel, and sexual function.
Structured pain generator mapping using targeted blocks to distinguish abdominal wall/trocar-site neuropathic pain from deep visceral pelvic pain— especially important after multiple prior surgeries.
Organ-function endpoints treated as core outcomes, with bladder and bowel symptom pathways integrated into pelvic pain decision-making.

DISCOVER THE

The Pelvic Neurofunctional Medicine Model

Principle: Identify the generator. Match the therapy.

Pelvic pain and pelvic dysfunction commonly involve overlapping generators:

Disease-Driven Generators

Endometriosis and Structural Pathology

Myofascial and Pelvic

Floor Generators

Neuropathic Generators

Peripheral Nerve Injury or Sensitization

Visceral Hypersensitivity

And Autonomic Dysregulation

DISCOVER THE

Nerve Blocks

At ESSI, nerve blocks are used for immediate symptom relief and as diagnostic mapping tools. A correctly chosen block can help distinguish abdominal wall or peripheral nerve pain from deep visceral pelvic pain.

This distinction is particularly important after multiple prior surgeries, where trocar sites or fascial closure can contribute to neuropathic pain that mimics internal pelvic pain.

Core block categories used in pelvic pain phenotyping:

Abdominal Wall and Groin Blocks

Ilioinguinal block
Iliohypogastric block
Genitofemoral block (selected patterns)
Abdominal cutaneous nerve / trigger-point injections
Abdominal wall blocks such as TAP or rectus sheath techniques (selected).

Pudendal Nerve Block

Used when pain maps to pudendal distribution (perineal pain, sitting intolerance, sexual pain phenotypes). Response to anesthetic pudendal block is incorporated into widely used diagnostic criteria for pudendal neuralgia.

Ganglion Impar Block

Used when pain is centered in the perineum/coccyx region with burning or sympathetic-maintained features.

Superior Hypogastric Plexus Block (selected)

Used to evaluate and treat visceral pelvic pain pathways and has been studied in chronic pelvic pain in the presence of endometriosis.

Therapeutically, blocks can reduce guarding cycles, enable pelvic floor rehabilitation, reduce pain amplification, and guide next steps (repeat blocks, pelvic Botox, neuromodulation, or targeted surgical release when true entrapment is identified).

PILLAR II

Neuromodulation | Neurostimulation

Neuromodulation involves the use of targeted electrical signaling to regulate dysregulated nerve circuits.

It is utilized when pelvic pain is linked to autonomic signaling imbalances, particularly when symptoms overlap between the bladder, bowel, and pelvic floor.

Core block categories used in neuromodulation are:

Sacral Neuromodulation (SNM)

Sacral neuromodulation acts as a regulatory interface for the pelvic nerves. It utilizes a small implanted device to send mild electrical pulses to the sacral nerves, which control the bladder, bowel, and pelvic floor.

Neuromodulation in Bowel Pathways

This approach addresses the neuro-immune axis of the gut. Because the bowel’s immune response is tightly connected to autonomic pathways, targeted nerve stimulation is used to modulate the inflammatory environment.Used when pain maps to pudendal distribution (perineal pain, sitting intolerance, sexual pain phenotypes). Response to anesthetic pudendal block is incorporated into widely used diagnostic criteria for pudendal neuralgia.

Within a multidisciplinary model, this serves as a bioelectronic strategy for complex pelvic disease involving bowel dysfunction.

Vagus Nerve Stimulation (VNS)

Vagus nerve stimulation targets the brain–gut–immune axis. It is used to address the principle that pelvic symptom syndromes are often driven by dysregulated systemic signaling rather than local anatomy alone.

VNS helps regulate the broader neuro-immune pathways that contribute to chronic pelvic pain and functional disorders.

PILLAR III

Botox in Pelvic Neurofunctional Medicine

Botulinum toxin (Botox) is used in pelvic medicine to reduce pathologic contraction and improve pain and function by modifying neuromuscular signaling.

ESSI uses pelvic Botox in a precision, phenotype-driven way across three major domains: bladder, pelvic floor/anorectal, and uterus.

Core block categories where botox is used in neuromodulation are:

Bladder Botox for urgency-frequency and neurogenic irritability phenotypes

Many patients labeled with “interstitial cystitis” present with urgency-frequency syndromes and neurogenic bladder irritability that can be driven by endometriosis-associated cross-sensitization, pelvic floor hypertonicity, and broader pelvic dysfunction. ESSI treats classic interstitial cystitis as a specific diagnosis rather than a default label and evaluates whether a neurogenic irritability phenotype is the primary driver. 

When minimally invasive pelvic surgery is already planned, ESSI may favor robotic or laparoscopic delivery of bladderBotox in selected scenarios to reduce mucosal trauma that can occur with repeated transmucosal instrumentation in sensitized bladders.

ESSI generally avoids repeated bladder instillations and routine bladder dilation/hydrodistention as long-term strategies in pelvic pain populations due to concerns about procedural trauma and limited durability of benefit in many cases.

Pelvic floor Botox (levator ani hypertonicity and anorectal spasm phenotypes)

Pelvic floor hypertonicity is a frequent secondary driver in endometriosis and chronic pelvic pain. Guarding and spasm can perpetuate dyspareunia, rectal pain, urgency-frequency symptoms, and evacuation dysfunction. Pelvic floor Botox is used to reduce levator spasm, improve tolerance of pelvic floor therapy, and reduce pain amplification.

Pelvic floor Botox is performed intraoperatively as part of comprehensive surgery when indicated and in outpatient settings when pelvic floor tone is a dominant generator or surgery is not indicated.

Uterine Botox for intractable dysmenorrhea and adenomyosis-related pain (selected)

Uterine hypercontractility can be a major driver of severe dysmenorrhea in adenomyosis-associated phenotypes.

Intramyometrial botulinum toxin has published clinical evaluation in severe dysmenorrhea and pelvic pain populations and remains an evolving area. Within ESSI’s organ-sparing strategy, uterine Botox is evaluated in carefully selected cases when contraction-driven pain is strongly suspected.